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and Jan M. Provis1,2,3
PURPOSE. To investigate the expression and localization of com-
plement system mRNA and protein in a light-induced model of
progressive retinal degeneration.
METHODS. Sprague-Dawley (SD) rats were exposed to 1000 lux
of bright continuous light (BCL) for up to 24 hours. At time
points during (1–24 hours) and after (3 and 7 days) exposure,
the animals were euthanatized and the retinas processed. Dif-
ferential expression of complement genes at 24 hours of ex-
posure was assessed using microarray analysis. Expression of
complement genes was validated by quantitative PCR, and
expression of selected genes was investigated during and after
BCL exposure. Photoreceptor apoptosis was assessed using
TUNEL and C3 was further investigated by spatiotemporal
analysis using in situ hybridization and immunohistochemistry.
RESULTS. Exposure to 24 hours of BCL induced differential
expression of a suite of complement system genes, including
classic and lectin components, regulators, and receptors.
C1qr1, MCP, Daf1, and C1qTNF6 all modulated in concert
with photoreceptor death and AP-1 expression, which reached
a peak at 24 hours exposure. C1s and C4a reached peak
expression at 3 days after exposure, while expression of C3,
C3ar1, and C5r1 were maximum at 7 days after exposure. C3
mRNA was detected in ED1- and IBA1-positive microglia/mac-
rophages, in the retinal vessels and optic nerve head and in the
subretinal space, particularly at the margins of the emerging
lesion.
CONCLUSIONS. The data indicate that BCL induces the prolonged
expression of a range of complement genes and show that
microglia/macrophages synthesize C3 and deposit it in the
ONL after BCL injury. These findings have relevance to the role
of complement in progressive retinal degeneration, including
atrophic AMD. (Invest Ophthalmol Vis Sci. 2011;52:5347–5358)
DOI:10.1167/iovs.10-7119
The complement system is a component of the innate im-mune system, which provides a rapid host defense against
a range of immunologic challenges.1,2 Through a cascade of
proteolytic cleavages that generate phagocytosis-enhancing op-
sonins, chemotactic anaphylatoxins, and membrane-attack
complexes,3,4 the activity of this system complements the
ability of the host to initiate humoral defenses against infec-
tious pathogens5 and promotes the removal of potentially nox-
ious substances, including extracellular debris,1,3,4,6 immune
complexes,2,7–9 and apoptotic cells.8,10–13
Despite this beneficial function, a pathogenic role of com-
plement in age-related macular degeneration (AMD) has been
uncovered through gene association studies. These identify a
significant association between the Y402H sequence variant in
the regulatory gene complement factor H (CFH) with inci-
dence of AMD,14–17 along with other susceptibility variants in
complement pathway genes such as C2,18,19 CFB,18,19 and the
central component C3.20–24 These findings firmly establish
complement activation and inflammation as factors that in-
fluence the onset and progression of AMD. Furthermore,
histologic analyses of AMD donor eyes show that comple-
ment components and regulatory proteins are present in
drusen,18,25,26 suggestive of chronic complement activation.
However, several key aspects of the disease process remain
unclear, including the cellular events that promote comple-
ment activity in the retina.18
Some investigations have shown that the light-mediated
model of retinal degeneration in rats has pathogenic features in
common with atrophic AMD,27–31 and it has been shown that
ablation of the alternative pathway gene complement factor D
(CFD) in this model attenuates photoreceptor death.32 To
better understand the role of complement in the degenerative
process, in this study we sought to investigate the transcrip-
tional profile and spatiotemporal distribution of complement
gene expression in relation to areas of photoreceptor loss in
the retina after damaging light. We found that photoreceptor
death is accompanied by robust expression of complement-
related genes, many of which are associated with degeneration
that takes place sometime after the damaging stimulus. Further,
we found synthesis of C3 in the retina by infiltrating microglia/
macrophages, in spatiotemporal coincidence with photorecep-
tor degeneration in the atrophic lesion.
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METHODS
Animals and Light Exposure
All experiments conducted were in accordance with the ARVO State-
ment for the Use of Animals in Ophthalmic and Vision Research.
Sprague-Dawley (SD) rats aged from 130 to 160 postnatal days were
exposed to bright continuous light (BCL) at 1000 lux according to
protocols described previously.28 The animals were exposed to BCL
for a period of 1, 3, 6, 12, 17, or 24 hours, after which time retinal
tissue was obtained for analysis. Some animals were returned to dim-
light (5 lux) conditions immediately after 24 hours of BCL for a period
of 3 or 7 days, to assess postexposure effects. Age-matched, dim-reared
animals served as control samples.
Tissue Collection and Processing
Animals were euthanatized by overdose of barbiturate administered
by an intraperitoneal injection (60 mg/kg bodyweight; Valabarb;
Virbac Animal Health, Regents Park, NSW, Australia). The left eye
from each animal was marked at the superior surface for orientation
and then enucleated and processed for cryosectioning, and the retina
from the right eye was excised through a corneal incision and prepared
for RNA extraction.
Eyes for cryosectioning were immediately immersion fixed in 4%
paraformaldehyde in 0.1 M PBS (pH 7.3) for 3 hours at room temper-
ature, then processed as previously described28 and cryosectioned at
16 !m. Retinas for RNA extraction were immediately deposited in RNA
stabilizer (RNAlater; Ambion, Austin, TX), prechilled on ice, and stored
according to the manufacturer’s instructions. RNA was then extracted
from each sample according to a methodology established previ-
ously.33 Isolated total RNA was analyzed for quantity and purity with a
spectrophotometer (ND-1000; Nanodrop Technologies, Wilmington,
DE), and samples with a 260/280 ratio greater than 1.90 were consid-
ered sufficient. The RNA quality in each sample was assessed (2100-
Bioanalyzer; Agilent Technologies, Santa Clara, CA) where only sam-
ples with an integrity number (RIN) of "8 were used.
Microarray Experimentation and Analysis
Microarray analysis was performed using raw microarray data derived
from a previous study conducted by members of our group, using rat
gene microarrays (Rat Gene 1.0 ST; Affymetrix, Santa Clara, CA).34 The
full set of microarray data has been deposited in the NCBI Gene
Expression Omnibus repository under accession number GSE22818
(National Center for Biotechnology Information, National Institutes of
Health, Bethesda, MD). The analysis compared samples from dim-
reared and 24-hour BCL experimental groups (n ! 3 for each). The
microarray data were analyzed (Partek Genomics Suite 6.4 software;
Partek Inc., St. Louis, MO), and CEL files (Affymetrix) were imported
into the software with background correction, normalization, and
summarization, using the robust multiarray average (RMA) algorithm
adjusted for probe sequence and GC content (GC-RMA). The pro-
cessed values were displayed as individual probe sets representing
exonic coding sequences, which were log-transformed using base 2.
Differential expression analysis was performed using the analysis of
variance (ANOVA) statistic with significance level of P " 0.05.
The heterogeneity of the resulting differential expression data
was evaluated with agglomerative hierarchical clustering, using the
Euclidean distance metric and principle component analysis (PCA;
both provided by the Genomics Suite; Partek). The differential
expression data were then clustered according to biological process
as described by the Gene Ontology Consortium,35 using functional
analysis with Gene Ontology (GO) enrichment provided by the
software (Partek GS Genomics Suite).36 After this, the list of differ-
entially expressed genes was screened for those relating to the
complement cascade, using a differential expression cutoff of #50%
and aided by pathway information summarized from the Gene
Ontology Consortium35 and gene grouping from the HUGO Gene
Nomenclature Committee.37
Quantitative Real-Time Polymerase
Chain Reaction
First-strand cDNA synthesis was performed as described previously.33
Gene amplification was measured using either commercially available
hydrolysis probes (TaqMan; Applied Biosystems, Inc. [ABI], Foster
City, CA) or SYBR Green with custom designed primers, the details of
which are provided in Tables 1 and 2, respectively. The hydrolysis
probes were applied according to a previously established qPCR pro-
tocol.33 The primers for SYBR Green qPCR (Table 2) were designed
within a coding domain sequence transversing an intron using the
Primer3 web-based design program.38 The qPCR was performed using
a commercial qPCR system (StepOnePlus; ABI). The amplification for
each biological sample was performed in experimental triplicate, with
the mean Cq (quantitation cycle) value then used to determine the ratio
of change in expression. For both qPCRs (Taqman and SYBR Green;
ABI), the percentage change compared to dim-reared samples was
determined using the $$Cq method. The expression of the target gene
was normalized to the expression of the reference gene glyceralde-
TABLE 1. Genetic Analysis Probes
Gene Symbol Gene Name Catalog Entrez Gene ID*
C1s Complement component 1, s subcomponent Rn00594278_m1 NM_138900.1
CD93 (C1qr1) CD93 molecule (Complement component 1, q subcomponent receptor 1) Rn00584525_g1 NM_053383.1
C1qtnf6 C1q and tumor necrosis factor related protein 6 Rn01504712_m1 NM_001034932.1
C3 Complement component 3 Mm00437858_m1 NM_009778.2
C3ar1 Complement component 3a receptor 1 Rn00583199_m1 NM_032060.1
C4b Complement component 4, gene 1 (C4B) Rn00709527_m1 NM_031504.2
C5r1 Complement component 5a receptor 1 Rn02134203_s1 NM_053619.1
CD55 (Daf1) CD55 molecule (Decay accelerating factor 1) Rn00709472_m1 NM_022269.2
GAPDH Glyceraldehyde-3-phosphate dehydrogenase Rn99999916_s1 NM_017008.3
Jun (AP-1) Jun oncogene (transcription factor AP-1) Rn99999045_s1 NM_021835.3
* National Center for Bioechnology Information, National Institutes of Health, Bethesda MD. http://www.ncbi.nlm.nih.gov/sites/gene.
TABLE 2. qRT-PCR Custom Primer Sets
Gene Symbol NCBI RefSeq Forward Primer (5!–3!) Reverse Primer (5!–3!)
CD46 (MCP) NM_019190.1 CTCTTGGGAGCCCTCTATCC ATTCCTTCACGGGGACTAGG
GAPDH NM_017008.3 CCTGGAGAAACCTGCCAAG CCTCAGTGTAGCCCAGGATG
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hyde-3-phosphate dehydrogenase (GAPDH), which showed no differ-
ential expression in the present study or in previous light-induced
retinal damage investigations.32,39 Amplification specificity was as-
sessed using gel electrophoresis. Statistical analysis was performed
using the one-way ANOVA, to assess the significance of the trend in
expression. Differences with a P " 0.05 were considered statistically
significant.
In Situ Hybridization
To investigate the localization of C3 mRNA transcripts in the retina
after BCL, a riboprobe to C3 was generated for in situ hybridization on
retinal cryosections. C3 was cloned from a PCR product (483-bp
amplicon) using cDNA prepared from rat retinas (as described above),
the pGEM-T DNA vector system (Promega, Madison, WI), and TOP10
competent cells (One Shot; Invitrogen). A DIG RNA-labeling kit (SP6/
T7; Roche, Basel, Switzerland) was used to transcribe linearized plas-
mid and generate DIG-labeled antisense and sense riboprobes. In situ
hybridization was performed with a protocol described previously40;
the C3 riboprobe was hybridized overnight at 57°C, and then washed
in saline sodium citrate (pH 7.4) at 60°C. After hybridization, some
sections were further stained immunohistochemically (described
later).
Analysis of Cell Death
TUNEL labeling was used to quantify photoreceptor apoptosis in cryo-
sections, during and after BCL, with a protocol published previously.41
Counts of TUNEL-positive cells in the outer nuclear layer (ONL) were
performed along the full-length of retinal sections cut in the parasag-
ittal plane (superioinferior), including the optic disc, in adjacent fields
measuring 1000 % 1000 !m. The final count from each animal is the
average at comparable locations in two nonsequential sections. Statis-
tical analysis was performed by using one-way ANOVA. Differences
with a P " 0.05 were considered statistically significant.
Immunohistochemistry
Cryosections from each time point were used for immunohistochem-
ical analysis, using primary antibodies for complement C3 (1:50; Ab-
cam, Cambridge, MA), C3d (1:100; R&D Systems, Minneapolis, MN),
ED1 (1:200; Millipore, Billerica, MA), and IBA1 (1:1000; Wako, Osaka,
Japan). Immunohistochemistry was performed using a methodology
previously described.33 Immunofluorescence was viewed with a laser
scanning microscope (Carl Zeiss Meditec, Inc.) and acquired using PAS-
CAL software (ver. 4.0; Carl Zeiss Meditec, Inc.). Images were enhanced
for publication (Photoshop; Adobe, San Jose, CA), which was standard-
ized between images.
RESULTS
Microarray Analysis
Analysis of microarray data compared gene expression in reti-
nas of animals reared in dim-light conditions with those ex-
posed to 24 hours of BCL. We compiled a list of differentially
expressed gene probe sets (P " 0.05) after BCL. Hierarchical
clustering dendrograms (Fig. 1A) generated from the resulting
microarray data showed strong homogeneity among biological
replicates for their respective conditions (dim-reared or BCL).
Principle component analysis (PCA; Fig. 1B) showed that 79%
of variance in gene expression among the six animals analyzed
TABLE 3. Highly Represented Clusters of Differentially Expressed
Genes after BCL
Gene
Ontology ID Biological Process
Enrichment
Score
GO:0050896 Response to stimulus 73.0
GO:0009987 Cellular process 50.0
GO:0032502 Developmental process 26.0
GO:0065007 Biological Regulation 26.0
GO:0016043 Cellular component organization 24.0
GO:0051234 Establishment of localization 20.0
GO:0022610 Biological adhesion 20.0
GO:0032501 Multicellular organismal process 16.0
GO:0008152 Metabolic process 15.0
GO:0040007 Growth 8.6
GO:0002376 Immune system process 6.3
GO:0044085 Cellular component biogenesis 3.2
FIGURE 1. Hierarchical clustering and
PCA of the processed microarray
gene expression data. (A) Hierarchi-
cal clustering data show that sample
replicates clustered closely accord-
ing to their condition, either dim-
reared or 24 hours of BCL. (B) PCA
analysis, where each circle repre-
sents a sample replicate, showed a
strong aggregation of replicates for
their condition across PC1 (x-axis),
which explains the most of the vari-
ance (79%).
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by microarray was due to light conditions (dim-reared or BCL),
showing high reproducibility in the microarray data.
A broad perspective on the differential gene expression in
these animals was achieved using Gene Ontology (GO) enrich-
ment clustering, according to biological process, from which a
list of the top 12 highly represented GO clusters was generated
(Table 3). The cluster with the largest enrichment score in-
cluded genes involved in response to stimulus (GO:0050896).
Within this cluster (data not shown), differentially expressed
genes include those involved in stimulus detection (GO:
0051606); response to external, chemical, and abiotic stimuli
(GO:0042221, GO:0009628, GO:0009605); stress response
(GO:0006950); and immune response (GO:0006955), which
in turn includes a cluster for complement activation (GO:
0006957).
Differential Expression of Complement Genes in
the Retina after BCL
Screening of the list of differentially expressed genes (P "
0.05) for those involved in the complement cascade resulted in
the identification of a total of 18 complement-related genes,
with a broad range of functional roles. Of the complement
activators, complement components C1s, C2, C3, and C4 (C4b,
and C4–2) were upregulated as a result of exposure to BCL, as
well as the carbohydrate recognition molecule ficolin B of the
lectin pathway. Increased expression of complement receptors
was observed, including integrin genes encoding the C3 recep-
tors CR3 (CD18/CD11b) and CR4 (CD18/CD11c), the C3 ana-
phylatoxin receptor C3ar1, and C1qr1. Several complement
regulators were also differently expressed after exposure to
TABLE 4. List of Differentially Expressed Complement System Genes after 24-Hour BCL Exposure
Gene Title Gene Symbol
% DE
(Light Damaged vs, Dim Reared) Probe Set ID*
Complement Activators (GO:0006956, GO:0006958, GO:0001867)
Complement component 1, s subcomponent C1s 170.55 10865444
330.74 10865449
87.38 10865443
Complement component 2 C2 93.51 10828172
Complement component 3 C3 138.55 10931755
296.04 10931730
133.06 10931752
Complement component 4, gene 1 C4b 203.91 10828234
Complement component 4, gene 2 C4–2 117.93 10828255
128.73 10828256
ficolin B Fcnb 152.44 10844013
93.29 10844006
Complement Binding Receptors (GO:0001848) and Integrins (GO:0008305)
CD93 molecule (Complement component 1, q receptor) CD93 (C1qr1) 96.85 10850534
212.17 10850536
54.98 10850535
175.39 10850532
Complement component 3a receptor 1 C3ar1 51.62 10865370
integrin beta 2 (CD18) (Complement receptor 3/4) CD18 (Itgb2) 84.13 10832317
integrin alpha M (CD11b) (Complement receptor 3, subunit 2) CD11b (Itgam) 122.52 10711273
202.00 10711276
233.02 10711291
318.97 10711272
96.09 10711286
integrin alpha X (CD11c) CD11c (Itgax) 282.41 10711305
(Complement receptor 4, subunit 2) 77.90 10711304
126.59 10711324
89.00 10711307
Regulators of Complement Activation (GO:0045916, GO:0001869, GO:0001971)
alpha-2-Macroglobulin a2m 121.17 10858410
70.62 10858418
81.77 10858426
64.64 10858433
CD46 molecule (membrane cofactor protein) CD46 (MCP) 64.55 10770837
111.28 10770835
87.89 10770833
CD55 molecule (decay accelerating factor) CD55 (Daf1) 94.87 10767402
Complement component 4 binding protein, beta C4bpb &63.15 10767442
&57.28 10767441
&70.96 10767440
&136.52 10767439
Serine (or cysteine) peptidase inhibitor, clade G, member 1 (C1NH) Serping1 54.07 10846859
Complement Related Genes
C1q and tumor necrosis factor related protein 3 C1qtnf3 &112.29 10813676
C1q and tumor necrosis factor related protein 6 C1qtnf6 62.45 10905309
* Affymetrix, Santa Clara, CA.
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BCL, including increased expression of cell-surface inhibitors
Daf1 (CD55) and MCP (CD46), soluble inhibitor SERPING1,
and a2m, whereas C4bp expression was reduced. In addition,
we observed modulation in the complement-related genes
C1qTNF3 and C1qTNF6, which belong to the C1q/TNF-related
protein (CTRP) family of adiponectin paralogs.42 We tested the
veracity of the data by analyzing the expression of eight of the
complement genes listed in Table 4, using comparative qPCR.
Expression of all eight genes corresponded well with the data
obtained from the microarrays (Fig. 2).
Modulation of Complement-Related Gene
Expression and Cell Death
We examined the temporal expression of these same eight
complement genes (Fig. 2) in relation to the number of TUNEL-
positive cells in the ONL and expression of the apoptosis-
related gene (Jun [AP-1]43; Fig. 3). We also included the ana-
phylatoxin receptor C5r1, in addition to the receptor C3ar1,
even though this gene was not annotated in the microarray at
the time of analysis. The temporal analysis spanned time points
during (1, 3, 6, 12, 17, and 24 hours) as well as after (3 and 7
days) BCL exposure. Our previous analysis shows that the
postexposure time points coincide with emergence of the
lesion in the area centralis.28
Consistent with our previous data,33 we observed large
increases in the number of TUNEL-positive nuclei in the ONL
after 12 hours of BCL, progressing to a prominent peak in cell
death at 24 hours of exposure (Fig. 3A). The number of TUNEL-
positive nuclei decreased substantially in the postexposure
period, at 3 and 7 days. We observed a significant upregulation
in AP-1 expression after 3 hours of BCL exposure, which
reached peak expression at 24 hours, coincident with peak cell
death and declined rapidly during the postexposure period
(Fig. 3A).
Expression of complement components C1s, C3, and C4b
(Fig. 3B) increased significantly between 12 and 24 hours of
BCL, and all three components reached peak expression in the
postexposure period. C1s and C4a reached peak expression at
3 days; the data do not show what happened to C3 expression
after its apparent peak at 7 days. The receptor C1qr1 reached
a peak expression in conjunction with the maximum cell death
and AP-1 expression, at 24 hours of BCL (Fig. 3C). In contrast,
expression of the complement receptors C3ar1 and C5r1
reached a peak at 3 to 7 days after exposure (Fig. 3C). The
present experiments do not show how prolonged the expres-
sion of these receptors might be. Expression of the comple-
ment inhibitors MCP and Daf1 reached a peak at 24 hours of
BCL (Fig. 3D), coincident with the peak in photoreceptor apo-
ptosis, with MCP showing the earlier and more robust expression
between 12 and 24 hours of exposure. C1qTNF6 showed modest
upregulation by 24 hours, followed by a gradual decrease during
the postexposure period (Fig. 3D).
Spatiotemporal Analysis of C3 Expression and
Immunoreactivity after BCL
Because of its pivotal role in the activation of all three com-
plement pathways and robust long-term upregulation after BCL
(Fig. 3B), we selected C3 for further characterization. Spatio-
temporal analysis of C3 expression was conducted by in situ
hybridization (Fig. 4). In dim-reared animals, C3 expression
was observed in sparsely distributed nuclei associated with the
superficial retinal vasculature (Fig. 4A). After 24 hours of BCL,
we detected a substantial increase in these C3-positive cells in
the retinal vasculature, which were preferentially recruited
into the superior retina (Figs. 4B, 4C), where a hotspot in
photoreceptor death has been described previously.28 C3-ex-
pressing nuclei showed continued recruitment to the retinal
vasculature in spatial correlation with the developing lesion at
3 days after exposure (Fig. 4D), and were also detected in
vessels at the optic nerve head (Figs. 4E, 4F). By 7 days after
exposure, C3-expressing cells were still present in large num-
bers in the retinal vasculature and optic nerve head (data not
shown) and were also observed in association with the degen-
erative remains of photoreceptors in the superior retina (Figs.
4G, 4H). Accumulations of C3-expressing cells were particu-
larly abundant within the ONL and subretinal space at the
margin of the lesion by 7 days after exposure (Figs. 4J–L). Few
to none of these were present in nonlesion areas of the retina
at 7 days (Fig. 4I). The identity of these C3-expressing cells was
determined with the microglia/macrophage markers IBA1
(Figs. 4M–O) and ED1 (Figs. 4Q–U). Most C3-expressing cells
were immunoreactive (IR) for IBA1, mainly within the ONL
and subretinal space associated with the lesion (Figs. 4M–O),
and some with ramified morphology (Fig. 4N-O, asterisks). IR
FIGURE 2. Comparative qPCR vali-
dation of differentially expressed
genes at 24 hours of BCL. Several
significantly (*probeset where P "
0.05) differentially expressed mi-
croarray genes were selected for
comparative expression analysis us-
ing qPCR. Consistent increases were
detected by qPCR for each gene,
which confirmed the increases in mi-
croarray gene expression. The trends
in qPCR expression were generally
higher than those in the microarray,
particularly for C1qr1 and C3ar1.
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for ED1 was also shown by some C3-expressing nuclei, such as
those associated with the subretinal space in and around the
lesion (Figs. 4Q–U).
IR for C3 protein was performed using antibodies against
whole C3 (Figs. 5A–J), and the long-lived cleavage fragment,
C3d (Fig. 5K-M).44 C3 was detected faintly within the retinal
vasculature and choroid of dim-reared animals (Fig. 5A). Similar
levels of expression were detected in animals exposed to 24
hours of BCL (data not shown). However, at 3 days after
exposure, we detected emerging C3-IR in the layer of outer
segments at the site of the developing lesion (Fig. 5B). Areas
outside the lesion were only faintly C3-IR (Fig. 5C). By 7 days
after exposure, C3-IR was more intense (Figs. 5D–I) and
formed multiple deposits throughout the ONL within the
‹
FIGURE 4. In situ hybridization for C3 mRNA in the retina after exposure to BCL. (A) In retinas from dim-reared animals, expression of C3 was
observed infrequently in nuclei associated with the superficial vasculature (arrowhead). (B, C) After 24 hours of BCL, C3-positive nuclei were
preferentially recruited to the retinal vasculature in the superior retina (B, arrowheads); no such infiltration was found in the inferior (C). (D) The
recruitment of C3-positive nuclei in the retinal vasculature continued 3 days after exposure, in association with the developing lesion (arrow-
heads). (E, F) Robust infiltration of C3-positive nuclei was observed in association with the optic nerve head at 3 days after exposure. (G–I) By
7 days after exposure, C3-positive nuclei had infiltrated the ONL and subretinal space within the lesion (G, H), whereas nonlesion areas in the
inferior retina remained comparable to dim-reared animals (I). (J–L) Seven days after exposure a large number of C3-positive nuclei aggregated at
the edges of the lesion. (M–P) C3 expression (dark gray) in sections counterimmunolabeled with anti-IBA1 (green), showing immunoreactivity
in many C3-expressing nuclei within the degenerating ONL (white arrowheads); some of these cells were ramified (!). (Q–U) C3 expression (dark
gray) in sections counterimmunolabeled with anti-ED1 (green), showing immunoreactivity in some of the C3-expressing nuclei associated with the
edge of the lesion (white arrowheads). C, choroid; GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; S, subretinal space.
FIGURE 3. Expression of validated complement genes (from Fig. 2) over a protracted BCL time course in relation to cell death markers. (A) The
frequency of TUNEL-positive nuclei in the ONL and expression of AP-1 were used as markers of apoptosis. Increases in TUNEL were observed after
12 hours of BCL, which progressed to a peak at 24 hours. The number of TUNEL-positive nuclei decreased substantially in the postexposure period.
AP-1 increased rapidly from 3 hours of BCL onward to reach a peak at 24 hours, and then tapered off rapidly by 3 days after exposure. (B)
Upregulation of complement components C1s, C3, and C4b occurred between 12 and 24 hours of BCL, and remained substantially upregulated,
particularly C3, in the postexposure period. (C) Expression of complement receptors C1qr1, C3ar1, and C5r1 increased substantially by 17 hours
of BCL. C3ar1 and C5r1 continued to upregulate into the postexposure period, whereas C1qr1 reached a considerable peak at 24 hours before
falling rapidly. (D) MCP upregulated rapidly from 12 hours of BCL to reach a peak at 24 hours, whereas Daf1 also increased over a similar time
course. The complement-related gene C1qTNF6 was found to increase slightly after 24 hours of BCL, which decreased slightly over the
postexposure period. The trend in expression for all genes, as well as TUNEL, was significant by one-way ANOVA (P " 0.05).
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lesion area, in the subjacent subretinal space (Figs. 5D, 5E),
and in segments of the retinal vasculature (Fig. 5J). On the
margins of the lesion, we observed intense C3-IR in ONL
deposits (Figs. 5F, 5G) and on photoreceptor outer seg-
ments (Fig. 5H, 5I), coinciding with aggregations of C3-
expressing macrophages (Figs. 5J–L). IR for C3d showed
spatiotemporal distribution very similar to that of whole-C3
after BCL (Figs. 5K–O). In dim-reared animals, C3d-IR was
faintly detected in the choroid and retinal vasculature (Fig.
5K). By 7 days after exposure, C3d had accumulated in
FIGURE 4.
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FIGURE 5.
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numerous deposits situated in the ONL and subretinal space
within the lesion area (Figs. 5L, 5M), in close association
with photoreceptor cell bodies (Fig. 5M), and on photore-
ceptor outer segments at the lesion edge (Figs. 5N, 5O).
DISCUSSION
The results of this study confirmed robust differential expres-
sion in the neural retina of several complement system genes
after light-induced retinal degeneration. These data are consis-
tent with the findings in a previous microarray study.32 In
addition, we demonstrated several key findings that elaborate
on the role of complement in retinal damage induced by BCL.
First, by microarray analysis and qPCR, we showed modulation
of a suite of complement genes, including opsonin mediators
from classic and lectin pathways (C1s, C2, C4, and ficolin B),
complement receptors (C1qr1, C3ar1, C5r1, CR3, CR4), and
regulators (MCP, Daf1, SERPING1, C4bp, a2m), many of
which have not been reported previously.32 Second, we
showed the time course of modulation of some of these genes
in relation to increasing levels of photoreceptor apoptosis,
demonstrating persistence of upregulation beyond 24 hours of
exposure—the peak of cell death (C1s, C3, C4b, C3ar1, and
C5r1). Third, we showed that microglia/macrophages synthe-
size C3 which is preferentially deposited in the ONL and layer
of outer segments in the damaged region and at the margins of
the lesion in the postexposure period.
Microglia Synthesize C3 and Mediate
Photoreceptor Death in Damaged Retina
To our knowledge, this is the first investigation to specifically
identify cells expressing C3 in the degenerating retina and to
determine the spatiotemporal profile of C3 deposition in rela-
tion to the degenerating region. In this study, we demonstrated
C3 expression by microglia/macrophages IR for IBA1 and ED1,
in spatiotemporal correlation with degeneration of the supe-
rior retina and C3 deposition after exposure to BCL,28 suggest-
ing that these aggregating cells are responsible for the local
propagation of complement in the retina after light-induced
damage. The emergence of C3-expressing cells from within the
retinal vasculature and optic nerve head, rather than the pa-
renchyma, after BCL, suggests that C3 is expressed initially by
recruited macrophages/monocytes.43,45 This finding is also
supported by the immunoreactivity of some cells to the mono-
cyte/macrophage marker ED-146 and by other studies describ-
ing the synthesis of C3 by macrophages in vitro.47–50 Expres-
sion of C3 was observed in both ramified and nonramified
IBA1-positive cells in the subretinal space at 7 days after expo-
sure. This late expression of C3 by ramified cells suggests that
parenchymal microglia also synthesize C3,46 but are relatively
slow to respond to BCL in this synthesis, compared with
recruited monocytes. Our data strongly suggest that photore-
ceptors are a target of C3 deposition by infiltrating C3-express-
ing cells after BCL, as both C3 and C3d immunoreactivity was
closely associated with photoreceptor cell bodies and outer
segments in relation to the lesion.
The present findings suggest that retinal degeneration asso-
ciated with the developing lesion is mediated at least in part by
C3 deposited by C3-expressing microglia/macrophages. Al-
though complement activation has beneficial properties, such
as aiding in debris clearance by recruited phagocytes,4 com-
plement propagation has been shown to exacerbate photore-
ceptor death in light-induced damage,32 of which C3 is a vital
component that drives activation of all three complement
pathways. C3 is also crucial to the assembly of the C5 conver-
tase, a mediator of the MAC complex, which may induce
apoptosis or necrosis of host cells.51 Moreover, several studies
have shown that microglial activation and aggregation are
associated with photoreceptor degeneration in light-induced
damage.52,53 The association of microglia/macrophages at the
edge of lesion also suggests a role in chronic expansion of the
lesion characterized previously,28 although the localization of
C3-expressing microglia past 7 days after exposure is currently
unknown.
A Transcriptional Profile of Complement
Activation after BCL
The transcriptional profile of complement gene expression
after BCL provides insight into the breadth of complement
activation in this model and its likely roles in the degenerative
process. First, upregulation of macrophage receptors that rec-
ognize cleavage products of C3 (C3ar1, CR3, and CR4) and C5
(C5r1),54 after exposure to BCL, indicate extensive activation
of complement in the neural retina with the involvement of
phagocytic cells. Second, there is an apparent compensatory
upregulation of complement inhibitor genes (MCP, Daf1,
SERPING1, and a2m) associated with the peak in photore-
ceptor death. Of these, MCP attenuates all three complement
pathways55 and is expressed by photoreceptors.56 Increased
expression of MCP suggests activation of a protective mecha-
nism by stressed photoreceptors after BCL, in an attempt to
safeguard from deleterious complement activation. Third, we
found increased expression of many genes involved in the
clearance of apoptotic cells. Classic pathway complement
components (C1s, C2, and C4), as well as the C3-fragment
receptors CR3 and CR4, were expressed strongly after 24
hours of BCL. This pattern of expression is consistent with a
role in the removal of apoptotic cells,1,10–13 including uptake
of apoptotic cells by macrophages.57,58 However, the ablation
of C1q# in rd1 mice did not appear to delay the removal of
apoptotic cells, indicating that the classic pathway—or at least
C1q#—alone may not be sufficient to initiate their clearance.59
We also showed differential expression of the carbohydrate
recognition molecule ficolin B, which promotes the removal of
late-stage apoptotic cells through binding to DNA,60 mediated
by the lectin pathway. Upregulation of these genes suggests
that a role of complement activation in this model is the
efficient removal of apoptotic cells after BCL.
!
FIGURE 5. Immunoreactivity (IR) for whole-C3 (red) and C3d (green) in the retina after exposure to BCL. (A) IR for C3 was faintly detected in
the choroid and retinal vasculature of dim-reared retinas (arrows and arrowheads). (B, C) At 3 days after exposure C3-IR was observed in the layer
of degenerating outer segments in superior retina (B, arrowheads); inferior retina was largely unreactive to C3 (C). (D, E) At 7 days after exposure
C3-IR was intense in the ONL and subretinal space in association within the lesion. (F–I) At the edges of the lesion after 7 days, C3-IR was found
deposited within the ONL (F, arrowheads) and in the layer of outer segments (G, H, arrowheads). (J) Portions of superficial retinal vasculature
showed strong IR for C3 at 7 days after exposure. IR for C3d (K–M) showed a similar spatiotemporal distribution to C3. (K) C3d IR was faintly
detected in the choroid and retinal vasculature (data not shown) of dim-reared retinas. (L–O) In the lesion at 7 days after exposure, C3d-IR was
widespread in deposits in the ONL (arrowheads) and subretinal space (L, M); on the lesion edge, C3d-IR was detected on photoreceptor outer
segments (N, O, arrowheads). (!) Blood vessels. (P, Q) Negative controls showed no specific staining for either C3 or C3d. BV, blood vessel; C,
choroid; INL, inner nuclear layer; IPL, inner plexiform layer; ONL, outer nuclear layer; OS, outer segment layer; RPE, retinal pigment epithelium;
S, subretinal space.
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Conversely, our findings implicate complement activation
in exacerbating light-mediated retinal damage, where comple-
ment components (C1s, C3, and C4) and anaphylatoxin recep-
tors (C3ar1 and C5r1) showed persistent upregulation in the
postexposure period, despite the significantly lower levels of
photoreceptor death. These findings are indicative of chronic
propagation of complement long after its initial activation by
the damaging stimulus, and they correlate with the detrimental
effect of complement demonstrated by Rohrer et al.32 This
dichotomy in the effects of complement activation has been
documented previously,54,61–63 and likely reflects a disruption
of the balance between complement activation and inhibition.
In light-induced damage, this may be spurred by the abundance
of activating surfaces (apoptotic cells, debris) that arises after
the damaging stimulus. Given that alternative pathway activa-
tion is implicated in the mediation of light-induced degenera-
tion,32 chronic synthesis of classic components detected in this
study may stimulate further activation of complement through
the amplification loop initiated by the alternative pathway,64 as
demonstrated by Rohrer et al.65 in experimental choroidal
neovascularization.
Relevance to the Role of Complement in AMD
Previous studies have shown that light-induced damage in rats
has features in common with the pathogenesis of atrophic
AMD.27–31 Although the long-term features of atrophic AMD,
such as pigmentary disturbance and drusen, are absent from
this model, the development of a lesion aligned to the visual
axis,66 the characteristics of the lesion (which affect the pho-
toreceptor layer, RPE and Bruch’s membrane), and its progres-
sive nature occur in common with the atrophic AMD lesion.28
Like the widely used laser-induced model of neovascular AMD,
this model employs an acute damaging stimulus to evoke
long-term, site-specific changes in the retina and adjacent tis-
sues.
The cellular events that lead to the propagation of comple-
ment in the human retina are not well understood.18,67 None-
theless, it is well established that polymorphisms in a range of
complement-related genes is associated with risk of AMD,18
and the high levels of association between the Y402H poly-
morphism of the CFH gene and risk of AMD14–17 implicate
failure to regulate the alternative pathway of complement ac-
tivation with onset and progression of AMD. Experimental
findings using the present model of retinal degeneration impli-
cate activation of complement pathways in onset and progres-
sion of the retinal lesion, and show conclusively that microglia/
macrophages express C3, which is deposited in the
photoreceptor layer. In these conditions, photoreceptors may
become the target for activation of the alternative pathway,
which would culminate in the formation of MAC, cytolysis, and
cytotoxic cell death.51 Consistent with this as a mechanism in
AMD, the MAC complex has been identified in drusen of donor
eyes from individuals, with and without the at-risk Y402H
genotypes.68 Moreover, accumulation of microglial cells in the
macula is strongly associated with AMD pathology (Wong J, et
al. IOVS 2001;42:ARVO E-Abstract 1222).69–73 In the atrophic
form of AMD, photoreceptor and RPE degeneration on the
edges of the lesion results in progressive expansion of the
lesion,74 and a recent study has shown that macrophages
accumulate on the edges of AMD lesions.75 The present find-
ings suggest that these aggregations of macrophages are focal
points of C3 synthesis and deposition, which may actively
progress the elimination of photoreceptors in the vicinity, if
left unchecked. Indeed, several studies that have shown an
association in polymorphisms of C3 with the progression of
AMD to geographic atrophy.21,75–77 Defects in regulatory
genes, including CFH, may therefore predispose the photore-
ceptors to progressive degeneration through aberrant comple-
ment propagation induced by activated microglia/macro-
phages.
CONCLUSION
Our findings demonstrate that exposure to damaging light
induces prolonged spatiotemporal changes in the expression
of a suite of complement-related genes and further clarify the
role of complement in the progression of retinal degeneration.
Our evidence suggests that complement activation in the retina
has both positive and negative effects, being beneficial to the
maintenance of homeostasis after injury, yet harmful because
of sustained propagation of components beyond the immedi-
ate injury and clean-up period. The synthesis of C3 by micro-
glia/macrophages implicates their recruitment in the local ac-
tivation of complement after retinal damage. The findings
therefore suggest that therapeutic attenuation of microglial
recruitment may be useful strategy to control detrimental prop-
agation of complement in the retina.
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